Rchr
J-GLOBAL ID：201801019614276496   Update date: Oct. 31, 2024

wada satoshi

ワダ サトシ | wada satoshi
Affiliation and department：
Showa University

About Showa University


Other affiliations (1)：
  • Showa University  School of Medicine Department of Medicine, Division of Oncology 
Homepage URL  (1)： https://showa-oncology.jp
Research field  (2)： Tumor diagnostics and therapeutics ,  Gastroenterology
Research keywords  (3)： がん免疫療法 ,  腫瘍内科学 ,  tumor immunology
Research theme for competitive and other funds  (10)：
  • 2024 - 2028 ICI耐性NSCLCにおけるSiglec-9の役割
  • 2024 - 2027 ドライバー遺伝子変異に伴うPD-L1糖鎖構造の解明及び個別化治療への挑戦
  • 2024 - 2027 Analysis of EphA2/ephrin-A1-mediated PD-L1 expression and its clinical application
  • 2022 - 2025 Mechanism of Immune Cell Activation in theTumor Microenvironment of Colon Cancer with MTAP Deletion
  • 2021 - 2024 Analysis of Glycan Structures of Immune Checkpoint Molecules and Challenges for Personalized Therapy
Show all
Papers (97)：
  • Yuya Hirasawa, Yutaro Kubota, Emiko Mura, Risako Suzuki, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Ryotaro Ohkuma, Masahiro Shimokawa, Hirotsugu Ariizumi, et al. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment. Anticancer research. 2024. 44. 8. 3397-3407
  • Masakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu, Sei Kobayashi, Akiko Sasaki, Yuta Baba, Yoichiro Narikawa, Hitoshi Toyoda, Junya Isobe, Eiji Funayama, et al. Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. Scientific reports. 2024. 14. 1. 11325-11325
  • Masahiro Hosonuma, Yuya Hirasawa, Atsuo Kuramasu, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Yuta Baba, Junya Isobe, Eiji Funayama, Kohei Tajima, et al. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit. Cancer science. 2024. 115. 3. 752-762
  • Koji Otsuka, Junya Isobe, Yoshiyuki Asai, Tomohisa Nakano, Kouya Hattori, Tomotake Ariyoshi, Takeshi Yamashita, Kentaro Motegi, Akira Saito, Masahiro Kohmoto, et al. Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer. Cancer immunology, immunotherapy : CII. 2024. 73. 2. 23-23
  • Yuya Hirasawa, Yutaro Kubota, Emiko Mura, Risako Suzuki, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Ryotaro Ohkuma, Masahiro Shimokawa, Hirotsugu Ariizumi, et al. Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients. Frontiers in oncology. 2024. 14. 1449941-1449941
ｍore...
MISC (314)：
  • 和田 聡. 高密度レクチンアレイを用いた腫瘍抗原における糖鎖構造の解明. 昭和学士会雑誌. 2024. 84. 1. 75-81
  • 鶴井 敏光, 濱田 和幸, 村 英美子, 鈴木 梨沙子, 入口 菜々, 石黒 智之, 平澤 優弥, 大熊 遼太朗, 下川 雅弘, 有泉 裕嗣, et al. CT scanで分かるがん患者免疫能と免疫チェックポイント阻害剤の臨床効果. 日本癌治療学会学術集会抄録集. 2023. 61回. O1-5
  • 吉村 清, 細沼 雅弘, 磯部 順哉, 馬場 勇太, 田島 康平, 船山 英治, 豊田 仁志, 鶴井 敏光, 平澤 優弥, 有泉 裕嗣, et al. ICIの効果を増強するために便移植に向けた腸内細菌の探索. 日本癌治療学会学術集会抄録集. 2023. 61回. O19-1
  • 吉村 清, 浜田 和幸, 磯部 順哉, 細沼 雅弘, 馬場 勇太, 田島 康平, 船山 英治, 豊田 仁志, 鶴井 敏光, 平澤 優弥, et al. 免疫チェックポイント阻害剤と併用による便移植のための腸内細菌の探索(Exploring Gut Microbiome for Fecal Transplantation in Combination with Immune Checkpoint Inhibitors). 日本癌学会総会記事. 2023. 82回. 34-34
  • 家口 勝昭, 大西 伸幸, 大熊 遼太朗, 角田 卓也, 和田 聡. EphA2/ephrin-A1シグナル伝達を介したPD-L1の発現調節機構(Expression of PD-L1 is regulated by the EphA2/ephrin-A1 signaling pathway). 日本癌学会総会記事. 2023. 82回. 1829-1829
ｍore...
Professional career (1)：
  • 医学博士 (群馬大学)
Work history (2)：
  • 2018/05 - 現在 Showa University
  • 2018/05 - 現在 showa university clinical diagnostic oncology professor
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM